AbbVie Seeks Strict Interchangeability Standards For Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Interchangeability must be demonstrated for every indication on reference product's label even if biosimilar is not approved for all the same uses, AbbVie says in citizen petition filed three weeks after Amgen submitted a 351(k) application referencing Humira.